PAR · ALTHE.PA
Theraclion S.A.
€0.71-€0.03 (-4.59%)
Theraclion S.A.’s quoted price sits in the upper half of its reported 52-week range, 24.09% below the high.
Loading market information…
OTC · AFIB · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Acutus Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.29% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Acutus Medical, Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$0.95. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Acutus Medical, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Acutus Medical, Inc. is a company dedicated to the treatment of cardiac arrhythmias, focusing on the design, manufacturing, and commercialization of specialized tools for catheter-based ablation procedures. These solutions are utilized to manage a spectrum of heart rhythm disorders across both domestic U.S. and international markets. The firm's extensive product offerings include innovative access sheaths, transseptal crossing devices, diagnostic and mapping catheters, along with both traditional and contact-force ablation catheters. It also provides advanced mapping and imaging consoles, accompanying accessories, and vital supporting algorithms and software. Acutus Medical, Inc. was established in 2011 and is headquartered in Carlsbad, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:10 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $5.24M-21.0% vs estimate |
| Q2 2023 | Aug 7, 2023 | -$0.63-3.28% vs estimate | $5.29M+16.75% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€0.71-€0.03 (-4.59%)
Theraclion S.A.’s quoted price sits in the upper half of its reported 52-week range, 24.09% below the high.
$0.00$0.00 (0.0%)
LifePoint, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Capital Group Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.12% below the high.
$0.00$0.00 (0.0%)
Infinity Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.15% below the high.
$0.00$0.00 (0.0%)
Aridis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.6% below the high.
$0.00$0.00 (0.0%)
Winston Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
$0.00$0.00 (0.0%)
iCoreConnect Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.97% below the high.
$0.00$0.00 (0.0%)
Southwestern Medical Solutions, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.0% below the high.
